Original articleEn Face Enhanced-Depth Swept-Source Optical Coherence Tomography Features of Chronic Central Serous Chorioretinopathy
Section snippets
Methods
This study was performed under approved institutional review board protocols from the New England Eye Center and Massachusetts Institute of Technology. The research adhered to the tenets of the Declaration of Helsinki and complied with the Health Insurance Portability and Accountability Act of 1996. Signed informed consent was obtained before SS-OCT examination. Consecutive patients examined at the New England Eye Center between October 2012 and April 2013 with the clinical diagnosis of chronic
Results
Fifteen eyes of 13 patients seen consecutively and diagnosed with chronic CSCR were enrolled in the study. Their baseline characteristics were as follows: 11 male patients, 10 Caucasian and 3 Asian patients, mean age 50.7 years (standard deviation ± 9.5 years), and mean best-corrected visual acuity 20/50 (range, 20/20–20/800). All enrolled patients had a history of at least 6 months of visual symptoms in the affected eye(s). The mean period of time since initial presentation was 13.6 months
Discussion
Serous detachment of the neurosensory retina is characteristic of the typical presentation of CSCR, but the source of the subretinal fluid is still not completely agreed upon.1, 9 Retinal PEDs have been identified in up to 63% of affected eyes when studied with angiography and cross-sectional OCT imaging and may or may not be associated with neurosensory retinal detachments or clinical symptoms.9 Because FA shows focal, single, or multiple leaks from the RPE that are characteristic of the
References (43)
- et al.
Peripheral retinal detachments and retinal pigment epithelial atrophic tracts secondary to central serous pigment epitheliopathy
Ophthalmology
(1984) - et al.
The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980-2002
Ophthalmology
(2008) - et al.
The foveal photoreceptor layer and visual acuity loss in central serous chorioretinopathy
Am J Ophthalmol
(2005) - et al.
Central serous chorioretinopathy and glucocorticoids
Surv Ophthalmol
(2002) - et al.
Central serous chorioretinopathy in women
Ophthalmology
(1996) - et al.
Corticosteroids and central serous chorioretinopathy
Ophthalmology
(2002) - et al.
Endocrine abnormalities in patients with central serous chorioretinopathy
Ophthalmology
(2003) - et al.
Central serous chorioretinopathy after bone marrow transplantation
Am J Ophthalmol
(2001) - et al.
State-of-the-art retinal optical coherence tomography
Prog Retin Eye Res
(2008) - et al.
Enhanced depth imaging spectral-domain optical coherence tomography
Am J Ophthalmol
(2008)
A pilot study of enhanced depth imaging optical coherence tomography of the choroid in normal eyes
Am J Ophthalmol
Choroidal capillary and venous congestion in central serous chorioretinopathy
Am J Ophthalmol
Systemic findings associated with central serous chorioretinopathy
Am J Ophthalmol
Risk factors for central serous chorioretinopathy: a case-control study
Ophthalmology
Pathogenesis of disciform detachment of the neuroepithelium
Am J Ophthalmol
Type A behavior and central serous chorioretinopathy
Trans Am Ophthalmol Soc
Central serous chorioretinopathy in younger adults
Ophthalmology
Review and update of central serous chorioretinopathy
Curr Opin Ophthalmol
Long-term follow-up of central serous chorioretinopathy
Br J Ophthalmol
Central serous chorioretinopathy: a review of epidemiology and pathophysiology
Clin Experiment Ophthalmol
Choroidal neovascularization and central serous chorioretinopathy
Can J Ophthalmol
Cited by (0)
Supplemental material is available at www.aaojournal.org.
Financial Disclosure(s): The author(s) have made the following disclosure(s): M.F.K. has a patent owned by MIT and licensed to Optovue, Inc. J.G.F. has personal financial interest in Optovue, Inc, and patents owned by MIT and licensed to Carl Zeiss Meditech, Inc, and Optovue, Inc. J.S.D. receives research support from Carl Zeiss Meditech, Inc, and Optovue, Inc.
Support was provided by the National Institutes of Health (R01-EY011289-27, R01-EY013178-12, R01-EY018184-05, R44EY022864-01, R01-CA075289-16, R01-NS057476-05, and R44-EY022864-01); The Air Force Office of Scientific Research (AFOSR) (FA9550-10-1-0551 and FA9550-10-1-0063); Research to Prevent Blindness; Massachusetts Lions Club; and German Science Foundation DFG (DFG-GSC80-SAOT). The funding organizations had no role in the design or conduct of this research.